References
- United States Government Accountability Office. Science, business, regulatory and intellectual property issues cited as hampering drug development efforts. Report 07–49, November (2006).
- Drews J. The impact of cost containment on pharmaceutical research and development. Centre for Medicines Research Annual Lecture(1995).
- Drews J, Ryser S. Innovation deficit in the pharmaceutical industry. Drug Info. J.30(1), 97–108 (1996).
- Varki A, Rosenberg LE. Emerging opportunities and career paths for the young physician-scientist. Nat. Med.8(5), 437–439 (2002).
- Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol.14, 1516–1518 (1996).
- Drews J, Ryser S. Classic drug targets. Nat. Biotechnol.15, 1318–1319 (1997)
- Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Disc.1, 727–730 (2002).
- Overington JP, Al-Lazikami B, Hopkins AL. How many drug targets are there? Nat. Rev. Drug Disc.3, 993–996 (2006).
- Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol.16, 127–136 (2006).
- Drews J. What’s in a number? Nat. Rev. Drug Disc.5, 975 (2006).